Moderna ( (MRNA) ) is experiencing volatility. Read on for a possible explanation for the stock’s unusual movement.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Moderna shares have been volatile as investors weigh uncertain near-term COVID vaccine demand and limited visibility on future revenues. The company has updated a Phase 4 trial of its variant-containing mRNA booster in healthy adults aged 50–64, which could help secure recurring booster revenue if results are favorable. Still, with stiff competition and a more mature COVID vaccine market, analysts see any benefit from this trial as incremental, and have adjusted their valuations accordingly, keeping overall market sentiment cautious.
More about Moderna
YTD Price Performance: 33.47%
Average Trading Volume: 11,277,370
Technical Sentiment Signal: Hold
Current Market Cap: $15.86B
For further insights into MRNA stock on TipRanks’ Stock Analysis page.
See more of today’s top stock gainers and losers.